Nature Communications (May 2016)

Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies

  • M. Isabel Veiga,
  • Satish K. Dhingra,
  • Philipp P. Henrich,
  • Judith Straimer,
  • Nina Gnädig,
  • Anne-Catrin Uhlemann,
  • Rowena E. Martin,
  • Adele M. Lehane,
  • David A. Fidock

DOI
https://doi.org/10.1038/ncomms11553
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 12

Abstract

Read online

Antimalarial chemotherapy relies on combination therapies (ACTs) consisting of an artemisinin derivative and a partner drug. Here, the authors study the effects of globally prevalent mutations in a multidrug resistance transporter (PfMDR1) on the parasite’s susceptibility to ACT drugs.